Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

University of Guelph

$120,000.00

Combining tumour microenvironment remodelling and low dose metronomic chemotherapy to enhance treatment efficacy and preserve ovarian function and fertility in advanced stage cancers

EF 2025-26

Résumé
Ovarian cancer is the most lethal gynecological cancer, while pancreatic cancer is the third leading cause of cancer deaths in Canada. These cancers are often diagnosed at advanced stages, when treatments are less effective and options are limited. For many women, survival depends on multiple rounds of chemotherapy which, while lifesaving, is highly toxic to the ovaries, causing permanent egg loss and infertility. Many women face an impossible choice between eradicating cancer and preserving the chance to have children. Current fertility-preservation strategies, such as egg and embryo freezing, often require delaying cancer treatment and may not always succeed. There is an urgent need for therapies that do not force women to decide between fighting cancer and preserving their ability to have children. This study is testing a new approach that combines a gentler, continuous form of chemotherapy with a compound that improves blood flow of tumours. By normalizing tumour blood vessels, the compound enhances treatment delivery and effectiveness, while reducing damage to the ovaries. Using a mouse model, we will evaluate both cancer eradication and fertility outcomes, including hormone levels, egg quality, fertilization success, and the ability to produce healthy litters. If successful, this research could shift the treatment landscape for advanced cancers, offering women a future where survival does not come at the cost of their fertility or their hope of building a family.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
559517
Name
Lockington Cielle I
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Combining tumour microenvironment remodelling and low dose metronomic chemotherapy to enhance treatment efficacy and preserve ovarian function and fertility in advanced stage cancers
Programtype2
Studentship Programs
Orgnameinp2
University of Guelph
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Female Infertility; Fertility Preservation; Metronomic Chemotherapy; Oncofertility; Ovarian Cancer; Pancreatic Cancer
Abstract
Ovarian cancer is the most lethal gynecological cancer, while pancreatic cancer is the third leading cause of cancer deaths in Canada. These cancers are often diagnosed at advanced stages, when treatments are less effective and options are limited. For many women, survival depends on multiple rounds of chemotherapy which, while lifesaving, is highly toxic to the ovaries, causing permanent egg loss and infertility. Many women face an impossible choice between eradicating cancer and preserving the chance to have children. Current fertility-preservation strategies, such as egg and embryo freezing, often require delaying cancer treatment and may not always succeed. There is an urgent need for therapies that do not force women to decide between fighting cancer and preserving their ability to have children. This study is testing a new approach that combines a gentler, continuous form of chemotherapy with a compound that improves blood flow of tumours. By normalizing tumour blood vessels, the compound enhances treatment delivery and effectiveness, while reducing damage to the ovaries. Using a mouse model, we will evaluate both cancer eradication and fertility outcomes, including hormone levels, egg quality, fertilization success, and the ability to produce healthy litters. If successful, this research could shift the treatment landscape for advanced cancers, offering women a future where survival does not come at the cost of their fertility or their hope of building a family.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Lockington, Cielle I
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~